Dynavax Technologies EPS - Earnings per Share 2010-2022 | DVAX

Dynavax Technologies eps - earnings per share from 2010 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Dynavax Technologies Annual EPS
2021 $0.57
2020 $-0.78
2019 $-2.16
2018 $-2.55
2017 $-1.81
2016 $-2.92
2015 $-3.25
2014 $-3.45
2013 $-3.83
2012 $-4.10
2011 $-3.90
2010 $-6.90
2009 $-7.60
Dynavax Technologies Quarterly EPS
2022-03-31 $0.22
2021-12-31 $0.78
2021-09-30 $-0.24
2021-06-30 $0.02
2021-03-31 $0.01
2020-12-31 $0.15
2020-09-30 $-0.15
2020-06-30 $-0.53
2020-03-31 $-0.25
2019-12-31 $-0.39
2019-09-30 $-0.49
2019-06-30 $-0.66
2019-03-31 $-0.62
2018-12-31 $-0.64
2018-09-30 $-0.65
2018-06-30 $-0.63
2018-03-31 $-0.63
2017-12-31 $-0.42
2017-09-30 $-0.38
2017-06-30 $-0.41
2017-03-31 $-0.60
2016-12-31 $-0.57
2016-09-30 $-0.90
2016-06-30 $-0.75
2016-03-31 $-0.70
2015-12-31 $-0.66
2015-09-30 $-0.82
2015-06-30 $-0.80
2015-03-31 $-0.97
2014-12-31 $-0.85
2014-09-30 $-1.13
2014-06-30 $-0.94
2014-03-31 $-0.53
2013-12-31 $-0.93
2013-09-30 $-0.90
2013-06-30 $-0.90
2013-03-31 $-1.10
2012-12-31 $-1.10
2012-09-30 $-1.00
2012-06-30 $-0.90
2012-03-31 $-1.10
2011-12-31 $-0.20
2011-09-30 $-1.20
2011-06-30 $-0.90
2011-03-31 $-1.60
2010-12-31 $-1.20
2010-09-30 $-0.60
2010-06-30 $-3.40
2010-03-31 $-1.70
2009-12-31 $-7.50
2009-09-30 $-2.40
2009-06-30 $1.00
2009-03-31 $1.30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.215B $0.439B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
Biohaven Pharmaceutical Holding (BHVN) United States $9.996B 0.00
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00